Are­na sheds ties to weight drug Belviq, com­plet­ing a makeover

From now on, you can scratch any lin­ger­ing rep Are­na Phar­ma­ceu­ti­cals $AR­NA had as an obe­si­ty-fo­cused biotech. Four-and-a-half years af­ter the FDA ap­proved its weight drug Belviq for mar­ket­ing, and long af­ter vi­sions of block­buster sales van­ished like a mi­rage, the biotech has sold off rights to the drug to its part­ner Ei­sai and backed away from any re­main­ing fi­nan­cial com­mit­ment for fur­ther tri­al work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.